These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26614849)

  • 1. The frequency of pulmonary hypertension in patients with juvenile scleroderma.
    Adrovic A; Oztunc F; Barut K; Koka A; Gojak R; Sahin S; Demir T; Kasapcopur O
    Bosn J Basic Med Sci; 2015 Aug; 15(4):30-5. PubMed ID: 26614849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between global longitudinal strain and pulmonary function tests in patients with scleroderma and normal ejection fraction and pulmonary artery pressure: a case-control study.
    Hajsadeghi S; Mirshafiee S; Pazoki M; Moradians V; Mansouri P; Kianmehr N; Iranpour A
    Int J Cardiovasc Imaging; 2020 May; 36(5):883-888. PubMed ID: 32060775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
    Steen V; Medsger TA
    Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis.
    Steen V; Chou M; Shanmugam V; Mathias M; Kuru T; Morrissey R
    Chest; 2008 Jul; 134(1):146-51. PubMed ID: 18403670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.
    Fox BD; Shimony A; Langleben D; Hirsch A; Rudski L; Schlesinger R; Eisenberg MJ; Joyal D; Hudson M; Boutet K; Serban A; Masetto A; Baron M
    Eur Respir J; 2013 Oct; 42(4):1083-91. PubMed ID: 23258775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we predict the severity of pulmonary hypertension in patients with scleroderma?
    Acosta Colmán MI; Avila Pedretti G; Acosta ME; Simeón Aznar CP; Fonollosa Plá V; Villardel Torrés M
    Reumatol Clin; 2012; 8(5):259-62. PubMed ID: 22658662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension.
    Peled N; Shitrit D; Fox BD; Shlomi D; Amital A; Bendayan D; Kramer MR
    J Rheumatol; 2009 May; 36(5):970-5. PubMed ID: 19369472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated diffusing capacity reduction in systemic sclerosis.
    Steen VD; Graham G; Conte C; Owens G; Medsger TA
    Arthritis Rheum; 1992 Jul; 35(7):765-70. PubMed ID: 1622414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.
    Demir N; Şahin A; Küçükşahin O; Kayacan O; Dinçer İ; Sayın T; Karnak D; Turgay M
    Heart Lung Circ; 2014 Jul; 23(7):667-73. PubMed ID: 24613044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Right ventricular and pulmonary function in sickle cell disease patients with pulmonary hypertension.
    Akgül F; Yalçin F; Babayiğit C; Seyfeli E; Seydaliyeva T; Gali E
    Pediatr Cardiol; 2006; 27(4):440-6. PubMed ID: 16835804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolated DLco/VA reduction in systemic sclerosis patients: a new patient subset?
    Corzo P; Pros A; Martinez-Llorens J; Molina L; Ling SF; Balcells E
    Clin Rheumatol; 2018 Dec; 37(12):3365-3371. PubMed ID: 30368639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular assessment of asymptomatic patients with juvenile-onset localized and systemic scleroderma: 10 years prospective observation.
    Borowiec A; Dabrowski R; Wozniak J; Jasek S; Chwyczko T; Kowalik I; Musiej-Nowakowska E; Szwed H
    Scand J Rheumatol; 2012 Feb; 41(1):33-8. PubMed ID: 22103465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.
    Coghlan JG; Wolf M; Distler O; Denton CP; Doelberg M; Harutyunova S; Marra AM; Benjamin N; Fischer C; Grünig E
    Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29563168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).
    Kolstad KD; Li S; Steen V; Chung L;
    Chest; 2018 Oct; 154(4):862-871. PubMed ID: 29777655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
    Steen VD; Lucas M; Fertig N; Medsger TA
    J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study.
    Loth DW; Lahousse L; Leening MJG; Krijthe BP; Felix JF; Gall H; Hofman A; Ghofrani HA; Franco OH; Stricker BH; Brusselle GG
    Respir Med; 2017 Nov; 132():50-55. PubMed ID: 29229105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.
    Hsu VM; Chung L; Hummers LK; Shah A; Simms R; Bolster M; Hant FN; Silver RM; Fischer A; Hinchcliff ME; Varga J; Goldberg AZ; Derk CT; Schiopu E; Khanna D; Shapiro LS; Domsic RT; Medsger T; Mayes MD; Furst D; Csuka ME; Molitor JA; Saketkoo LA; Salazar CR; Steen VD
    J Rheumatol; 2019 Feb; 46(2):176-183. PubMed ID: 30275260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.